Grelz Henrik1,2, Midlöv Patrik3, Håkansson Anders4, Jakobsson Ulf3, Rivano Fischer Marcelo5,3, Ringqvist Åsa5,3. 1. Department of Neurosurgery and Pain Rehabilitation, Skåne University Hospital, Lasarettsgatan 13, 221 85, Lund, Sweden. Henrik.grelz@med.lu.se. 2. Center for Primary Health Care Research, Faculty of Medicine Department of Clinical Sciences Malmö, Lund University, Jan Waldenströms gata 35, 202 13, Malmö, Sweden. Henrik.grelz@med.lu.se. 3. Center for Primary Health Care Research, Faculty of Medicine Department of Clinical Sciences Malmö, Lund University, Jan Waldenströms gata 35, 202 13, Malmö, Sweden. 4. Department of Clinical Sciences Lund, Faculty of Medicine, Psychiatry, Lund University, Baravägen 1, 221 00, Lund, Sweden. 5. Department of Neurosurgery and Pain Rehabilitation, Skåne University Hospital, Lasarettsgatan 13, 221 85, Lund, Sweden.
Abstract
BACKGROUND: Opioids are still widely prescribed to long-term pain patients although they are no longer recommended for long-term treatments due to poor evidence for long-term efficacy, risks of serious side effects, and the possibility of inducing opioid hyperalgesia. In a Cochrane study from 2017, the authors identified an urgent need for more randomized controlled trials investigating the efficiency and effects of opioid tapering. The study aimed to assess (1) the efficiency of a structured intervention in causing stable reductions of opioid consumption in a population with long-term non-malignant pain and (2) effects on pain, pain cognitions, physical and mental health, quality of life, and functioning in response to opioid tapering. METHODS: The study is a randomized controlled trial. The sample size was set to a total of 140 individuals after estimation of power and dropout. Participants will be recruited from a population with long-term non-malignant pain who will be randomly allocated to (1) the start of tapering immediately or (2) the control group who return to usual care and will commence tapering of opioids 4 months later. A 12-month follow-up is included. When all follow-ups are closed, data from the Swedish drug register of the National Board of Health and Welfare will be collected and individual mean daily opioid dose in morphine equivalents will be calculated at three time points: baseline, 4 months, and 12 months after the start of the intervention. At the same time points, participants fill out the following questionnaires: Numeric Pain Rating Scale (NPRS), Tampa Scale of Kinesiophobia (TSK), Pain Catastrophizing Scale (PCS), Chronic Pain Acceptance Questionnaire (CPAQ-8), Hospital Anxiety and Depression Scale (HADS), and RAND-36. At baseline and follow-up, a clinical assessment of opioid use disorder is performed. DISCUSSION: A better understanding of the efficiency and effects of opioid tapering could possibly facilitate attempts to taper opioid treatments, which might prove beneficial for both the individual and society. TRIAL REGISTRATION: ClinicalTrials.gov NCT03485430 . Retrospectively registered on 26 March 2018, first release date. "Tapering of Long-term Opioid Therapy in Chronic Pain Population. RCT with 12 Months Follow up (TOPIO)." First patient in trial 22 March 2018.
RCT Entities:
BACKGROUND: Opioids are still widely prescribed to long-term painpatients although they are no longer recommended for long-term treatments due to poor evidence for long-term efficacy, risks of serious side effects, and the possibility of inducing opioid hyperalgesia. In a Cochrane study from 2017, the authors identified an urgent need for more randomized controlled trials investigating the efficiency and effects of opioid tapering. The study aimed to assess (1) the efficiency of a structured intervention in causing stable reductions of opioid consumption in a population with long-term non-malignant pain and (2) effects on pain, pain cognitions, physical and mental health, quality of life, and functioning in response to opioid tapering. METHODS: The study is a randomized controlled trial. The sample size was set to a total of 140 individuals after estimation of power and dropout. Participants will be recruited from a population with long-term non-malignant pain who will be randomly allocated to (1) the start of tapering immediately or (2) the control group who return to usual care and will commence tapering of opioids 4 months later. A 12-month follow-up is included. When all follow-ups are closed, data from the Swedish drug register of the National Board of Health and Welfare will be collected and individual mean daily opioid dose in morphine equivalents will be calculated at three time points: baseline, 4 months, and 12 months after the start of the intervention. At the same time points, participants fill out the following questionnaires: Numeric Pain Rating Scale (NPRS), Tampa Scale of Kinesiophobia (TSK), Pain Catastrophizing Scale (PCS), Chronic Pain Acceptance Questionnaire (CPAQ-8), Hospital Anxiety and Depression Scale (HADS), and RAND-36. At baseline and follow-up, a clinical assessment of opioid use disorder is performed. DISCUSSION: A better understanding of the efficiency and effects of opioid tapering could possibly facilitate attempts to taper opioid treatments, which might prove beneficial for both the individual and society. TRIAL REGISTRATION: ClinicalTrials.gov NCT03485430 . Retrospectively registered on 26 March 2018, first release date. "Tapering of Long-term Opioid Therapy in Chronic Pain Population. RCT with 12 Months Follow up (TOPIO)." First patient in trial 22 March 2018.
Authors: Andrew Kolodny; David T Courtwright; Catherine S Hwang; Peter Kreiner; John L Eadie; Thomas W Clark; G Caleb Alexander Journal: Annu Rev Public Health Date: 2015-01-12 Impact factor: 21.981
Authors: Roger Chou; Judith A Turner; Emily B Devine; Ryan N Hansen; Sean D Sullivan; Ian Blazina; Tracy Dana; Christina Bougatsos; Richard A Deyo Journal: Ann Intern Med Date: 2015-02-17 Impact factor: 25.391
Authors: H Birke; G P Kurita; P Sjøgren; J Højsted; M K Simonsen; K Juel; O Ekholm Journal: Acta Anaesthesiol Scand Date: 2016-02-09 Impact factor: 2.105
Authors: Gopal K Singh; Isaac E Kim; Mehrete Girmay; Chrisp Perry; Gem P Daus; Ivy P Vedamuthu; Andrew A De Los Reyes; Christine T Ramey; Elijah K Martin; Michelle Allender Journal: Int J MCH AIDS Date: 2019-08-08